Search Results | Blood | American Society of Hematology

1-20 of 231

Sort by

Sort Order Select

Journal Articles

Preoperative Transfusion in Pediatric Patient with Sickle Cell Disease

Mohamed Al Darwish, Sukainah Alabkary, Hajer Al deabel, Fatimah Alqatari, Wafa AlDubaisy

Blood (2019) 134 (Supplement_1): 4851.

DOI: https://doi.org/10.1182/blood-2019-127104

Published: 2019

Journal Articles

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

David J. Araten, MD, H. Leon Pachter, Robert J Dring, Elliot Newman, Steven M Cohen

Blood (2019) 134 (Supplement_1): 4795.

DOI: https://doi.org/10.1182/blood-2019-124571

Published: 2019

Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes

Blood (2019) 134 (Supplement_1): 1523.

DOI: https://doi.org/10.1182/blood-2019-123908

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

DOI: https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

DOI: https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type

Lori S Muffly, MD, Fran Maguire, PhD MPH, Qian Li, MS, Vanessa Kennedy, MD, Theresa H.M. Keegan, PhD MS

Blood (2019) 134 (Supplement_1): 421.

DOI: https://doi.org/10.1182/blood-2019-124992

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

DOI: https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

DOI: https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

DOI: https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Blood (2019) 134 (Supplement_1): 1302.

DOI: https://doi.org/10.1182/blood-2019-124882

Published: 2019

Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, DO, Ying Huang, MS, MA, Akwasi Agyeman, Amy S. Ruppert, MAS, PhD, Boyu Hu, MD, Natalie Turner, APRN, Renee Vadeboncoeur, MSN, APRN, Kerry A Rogers, MD, Seema A. Bhat, MD, Basem M. William, MRCP,MD, Samantha Jaglowski, MDMPH, Hank Lockman, Martha Glenn, MD, Rosa Lapalombella, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 4310.

DOI: https://doi.org/10.1182/blood-2019-124544

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

DOI: https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

DOI: https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Trisha Kissoon, MD MBA

Blood (2019) 134 (Supplement_1): 5062.

DOI: https://doi.org/10.1182/blood-2019-129511

Published: 2019

Journal Articles

Pegasperagase Toxicity in Adult Patients with Acute Lymphoblastic Leukemia: A Single Center Experience Comparing Patients Older and Younger Than 35 Years of Age

Jun H Choi, MD, Jacques Azzi, MD, Tsivia Hochman, MS, Mary Lynn R. Nierodzik, MD, Shella Saint Fleur-Lominy, MD PhD, Maher Abdul Hay, MD

Blood (2019) 134 (Supplement_1): 5067.

DOI: https://doi.org/10.1182/blood-2019-129041

Published: 2019

Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5292.

DOI: https://doi.org/10.1182/blood-2019-128435

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

DOI: https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Valentin Garcia Gutierrez, MD PhD, Luis Felipe Casado, Rosa Ayala, MD PhD, Fermin Sanchez-Guijo, MD PhD, Juan Carlos Hernandez Boluda, María Teresa Gomez Casares, Blanca Xicoy, MD MSc, Begonya Maestro, PhD, Juan Luis Steegmann, Arturo Garcia de Diego

Blood (2019) 134 (Supplement_1): 5904.

DOI: https://doi.org/10.1182/blood-2019-125627

Published: 2019

Journal Articles

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Zachary West, BS, Kristen Allen, MPH, Caitlin Monroe, MPH, Sharon M. Castellino, MD MSc, Tamara P. Miller, MDMSc

Blood (2019) 134 (Supplement_1): 5809.

DOI: https://doi.org/10.1182/blood-2019-131873

Published: 2019

Journal Articles

Voice of Cancer Patients: Patient Experience Regarding Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Sangeeta Aggarwal, MD, Singh Manish, B.Tech, Guroosh Chaudhary, Alok Aggarwal, PhD, Himanshu Punetha, M. Tech, Juhi Jha, Rahul Kumar Gond

Blood (2019) 134 (Supplement_1): 5843.

DOI: https://doi.org/10.1182/blood-2019-125195

Published: 2019

NARROW

Preoperative Transfusion in Pediatric Patient with Sickle Cell Disease

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Pegasperagase Toxicity in Adult Patients with Acute Lymphoblastic Leukemia: A Single Center Experience Comparing Patients Older and Younger Than 35 Years of Age

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Voice of Cancer Patients: Patient Experience Regarding Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only